New guidelines in the treatment of persistent central serous chorioretinopathy: PDT with half-dose verteporfin

Klin Monbl Augenheilkd. 2012 Apr;229(4):327-30. doi: 10.1055/s-0031-1299165. Epub 2012 Apr 11.

Abstract

Background: In persistent central serous chorioretinopathy (CSC) resolution of detachment can be achieved by photodynamic therapy. Our objective was to evaluate the efficacy of half-dose verteporfin compared to full-dose verteporfin.

Patients and methods: In 2009 the standard PDT regimen for CSC in our clinic was changed from full-dose to half-dose verteporfin. After a retrospective analysis 11 cases of half-dose PDT with documented course in 11 patients are presented. A comparison was performed with a control group of 11 consecutive patients with documented course who had received full-dose PDT before 2009.

Results: Prior to PDT there were no statistically significant differences between the groups concerning age, central foveal thickness, thickness of detachment, BCVA (EDTRS) and size of spot. 6 weeks after PDT a significant reduction of foveal thickness and detachment was detected in both groups, as well as a significant increase in BCVA. No statistically significant differences in outcome could be found between the two groups (Mann-Whitney U-test, p < 0.05).

Conclusions: PDT with half-dose verteporfin seems to be an effective and safe treatment for persistent CSC. Our data showed comparable results after half-dose and after full-dose PDT.

Publication types

  • Practice Guideline

MeSH terms

  • Central Serous Chorioretinopathy / drug therapy*
  • Chronic Disease
  • Dose-Response Relationship, Drug
  • Humans
  • Photochemotherapy / standards*
  • Photosensitizing Agents / administration & dosage
  • Photosensitizing Agents / standards
  • Porphyrins / administration & dosage*
  • Porphyrins / standards*
  • Retrospective Studies
  • Switzerland
  • Treatment Outcome
  • Verteporfin

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin